NEUROCRINE BIOSCIENCES INC
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity
| Accumulated Other Comprehensive Income (Loss) · Retained Earnings (Accumulated Deficit) | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Additional Paid-In Capital | ||||||
| (in millions) · Shares · $ · Total | ||||||
| Balance at December 31,2024 | 99.4 | $0.1 | $2,554.6 | $5.8 | $29.2 | $2,589.7 |
| Net income | — | — | — | — | 7.9 | 7.9 |
| Other comprehensive income, net of tax | — | — | — | 3.2 | — | 3.2 |
| Stock-based compensation expense | — | — | 52.8 | — | — | 52.8 |
| Issuances of common stock under stock plans | 1.2 | — | 32.1 | — | — | 32.1 |
| Repurchases of common stock | (1.6) | — | (107.6) | — | (42.4) | (150.0) |
| Balance at March 31, 2025 | 99.0 | $0.1 | $2,531.9 | $9.0 | $(5.3) | $2,535.7 |
| Balance at December 31,2023 | 98.7 | $0.1 | $2,382.0 | $7.0 | $(157.1) | $2,232.0 |
| Net income | — | — | — | — | 43.4 | 43.4 |
| Other comprehensive loss, net of tax | — | — | — | (3.7) | — | (3.7) |
| Stock-based compensation expense | — | — | 44.5 | — | — | 44.5 |
| Issuances of common stock under stock plans | 1.9 | — | 69.9 | — | — | 69.9 |
| Balance at March 31, 2024 | 100.6 | $0.1 | $2,496.4 | $3.3 | $(113.7) | $2,386.1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.